Literature DB >> 17320653

Health perceptions in patients who undergo screening and workup for prostate cancer.

David A Katz1, David F Jarrard, Colleen A McHorney, Stephen L Hillis, Donald A Wiebe, Dennis G Fryback.   

Abstract

OBJECTIVES: False-positive screening tests may induce persistent psychological distress. This study was designed to determine whether a positive screening test with negative biopsy findings for prostate cancer is associated with worsened mental health during short-term follow-up.
METHODS: We conducted a cross-sectional telephone survey of two groups of men approximately 2 months after testing: group 1, 109 men with an abnormal prostate-specific antigen level or digital rectal examination findings but with negative biopsy findings for prostate cancer; and group 2, 101 age-matched primary care patients with PSA screening levels in the reference range (less than 4 ng/mL). Primary outcomes included state anxiety and prostate cancer-related worry. Secondary outcomes included Medical Outcomes Study Short Form 36-item Health Survey subscales and sexual function items. Multivariate regression techniques were used to adjust for differences in baseline covariates.
RESULTS: Group 1 patients were more worried than group 2 patients about getting prostate cancer (mean worry 3.9 versus 4.5, P = 0.0001, using a 5-point scale, with 1 indicating extreme worry and 5 no worry). Group 1 patients also perceived their risk of prostate cancer to be significantly greater than that of controls (P = 0.001). No significant differences were found across state anxiety or Medical Outcomes Study Short Form 36-item Health Survey subscales. Sexual bother was greater for group 1 patients, with 19% reporting that sexual function was a moderate to big problem compared with 10% of group 2 patients (P = 0.0001).
CONCLUSIONS: Men with abnormal prostate cancer screening tests report increased cancer-related worry and more problems with sexual function, despite having a negative biopsy result. Effective counseling interventions are needed before prostate cancer screening and during follow-up.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17320653      PMCID: PMC1868466          DOI: 10.1016/j.urology.2006.09.059

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  27 in total

1.  The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association.

Authors:  M J Barry; F J Fowler; M P O'Leary; R C Bruskewitz; H L Holtgrewe; W K Mebust; A T Cockett
Journal:  J Urol       Date:  1992-11       Impact factor: 7.450

2.  Instrument development for health belief model constructs.

Authors:  V L Champion
Journal:  ANS Adv Nurs Sci       Date:  1984-04       Impact factor: 1.824

Review 3.  Prostate-specific antigen as a screening test for prostate cancer. The United States experience.

Authors:  C G Arcangeli; D K Ornstein; D W Keetch; G L Andriole
Journal:  Urol Clin North Am       Date:  1997-05       Impact factor: 2.241

4.  The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs.

Authors:  C A McHorney; J E Ware; A E Raczek
Journal:  Med Care       Date:  1993-03       Impact factor: 2.983

5.  The development of a six-item short-form of the state scale of the Spielberger State-Trait Anxiety Inventory (STAI).

Authors:  T M Marteau; H Bekker
Journal:  Br J Clin Psychol       Date:  1992-09

6.  Psychological reactions in men screened for prostate cancer.

Authors:  O Gustafsson; T Theorell; U Norming; A Perski; M Ohström; C R Nyman
Journal:  Br J Urol       Date:  1995-05

7.  Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values.

Authors:  D W Keetch; W J Catalona; D S Smith
Journal:  J Urol       Date:  1994-06       Impact factor: 7.450

Review 8.  Risks and complications of transrectal ultrasound guided prostate needle biopsy: a prospective study and review of the literature.

Authors:  L V Rodríguez; M K Terris
Journal:  J Urol       Date:  1998-12       Impact factor: 7.450

9.  Short-term effects of population-based screening for prostate cancer on health-related quality of life.

Authors:  M L Essink-Bot; H J de Koning; H G Nijs; W J Kirkels; P J van der Maas; F H Schröder
Journal:  J Natl Cancer Inst       Date:  1998-06-17       Impact factor: 13.506

10.  The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure.

Authors:  M S Litwin; R D Hays; A Fink; P A Ganz; B Leake; R H Brook
Journal:  Med Care       Date:  1998-07       Impact factor: 2.983

View more
  16 in total

1.  Remaining Life Expectancy Measurement and PSA Screening of Older Men.

Authors:  Ashwin A Kotwal; Supriya G Mohile; William Dale
Journal:  J Geriatr Oncol       Date:  2012-07-01       Impact factor: 3.599

2.  Psychological impact of serial prostate-specific antigen tests in Japanese men waiting for prostate biopsy.

Authors:  Minoru Kobayashi; Akinori Nukui; Takao Kamai
Journal:  Int J Clin Oncol       Date:  2016-09-08       Impact factor: 3.402

Review 3.  The quality-of-life impact of prostate cancer treatments.

Authors:  Jaspreet Singh; Edouard J Trabulsi; Leonard G Gomella
Journal:  Curr Urol Rep       Date:  2010-05       Impact factor: 3.092

4.  Risk perception and psychological morbidity in men at elevated risk for prostate cancer.

Authors:  A G Matthew; T Davidson; S Ochs; K L Currie; A Petrella; A Finelli
Journal:  Curr Oncol       Date:  2015-12       Impact factor: 3.677

5.  The Advantages of Transurethral Resection of the Prostate in Patients with an Elevated or Rising Prostate Specific Antigen, Mild or Moderate Lower Urinary Tract Symptoms, Bladder Outlet Obstruction and Negative Prostate Cancer Imaging or Prostate Biopsies: A Prospective Analysis in 105 Consecutive Patients.

Authors:  Evert Baten; Koenraad van Renterghem
Journal:  Curr Urol       Date:  2017-07-30

6.  Impact of prostate cancer testing: an evaluation of the emotional consequences of a negative biopsy result.

Authors:  R C Macefield; C Metcalfe; J A Lane; J L Donovan; K N L Avery; J M Blazeby; L Down; D E Neal; F C Hamdy; K Vedhara
Journal:  Br J Cancer       Date:  2010-04-06       Impact factor: 7.640

7.  Psychological distress after a positive fecal occult blood test result among members of an integrated healthcare delivery system.

Authors:  Sharon S Laing; Andy Bogart; Jessica Chubak; Sharon Fuller; Beverly B Green
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-11-12       Impact factor: 4.254

8.  Strategies for endometrial screening in the Lynch syndrome population: a patient acceptability study.

Authors:  K Elmasry; A J Davies; D G Evans; M N Seif; K Reynolds
Journal:  Fam Cancer       Date:  2009-06-13       Impact factor: 2.375

9.  Role of Hiraoka's transurethral detachment of the prostate combined with biopsy of the peripheral zone during the same session in patients with repeated negative biopsies in the diagnosis of prostate cancer.

Authors:  Chun-Yu Pan; Bin Wu; Zi-Chuan Yao; Xian-Qing Zhu; Yun-Zhong Jiang; Song Bai
Journal:  World J Clin Cases       Date:  2020-06-06       Impact factor: 1.337

Review 10.  A new algorithm in patients with elevated and/or rising prostate-specific antigen level, minor lower urinary tract symptoms, and negative multisite prostate biopsies.

Authors:  Koenraad van Renterghem; Gommert Van Koeveringe; Ruth Achten; Philip van Kerrebroeck
Journal:  Int Urol Nephrol       Date:  2009-06-03       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.